search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Effect of a new synbiotic mixture of short chain galacto-oligosaccharides, long chain fructo-oligosaccharides and Bifidobacterium strain on the gut microbiota of caesarean delivered infants.


- candidate number6811
- NTR NumberNTR2143
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR15-dec-2009
- Secondary IDsCae.1.C/B Danone Research B.V.
- Public TitleEffect of a new synbiotic mixture of short chain galacto-oligosaccharides, long chain fructo-oligosaccharides and Bifidobacterium strain on the gut microbiota of caesarean delivered infants.
- Scientific TitleEffect of a new synbiotic mixture of short chain galacto-oligosaccharides, long chain fructo-oligosaccharides and Bifidobacterium strain on the gut microbiota of caesarean delivered infants.
- ACRONYMJulius
- hypothesisThe study will investigate the effect of a synbiotic test product compared to a control product on the composition and metabolic activity of the gut microbiota of C-section delivered infants.
- Healt Condition(s) or Problem(s) studiedNeonates, Healthy full-term infants, Caesarean section, Vaginally birth
- Inclusion criteria1. Healthy term born neonates born to healthy pregnant mothers;
2. Mother is willing and able to comply with the protocol, including refrain from 2 weeks prior to study start (expected date of delivery) and for the duration of the study from the:
A. Use of probiotic supplements and food containing supplemented probiotics;
B. Use of prebiotic or fibre supplements;
C. Participation in any other intervention study.
3. Parents have given written informed consent.
- Exclusion criteriaFor the mothers:
1. Use of antibiotics (except antibiotic treatment related to CS) from 2 weeks prior to delivery for duration of the study;
2. Use of non-steriodal anti-inflammatory drugs (NSAIDs) from 2 weeks prior to delivery for duration of the study;
3. Fever 38.5 degrees or more during the last week before birth;
4. Blood pressure systolic °› 160 mm Hg and diastolic °› 100 mm Hg;
5. Occurrence of Eclampsia and Preeclampsia during the pregnancy;
6. Antenatal steroid treatment;
7. Antenatal antibiotics treatment (2 weeks before birth);
8. Diabetes mellitus requiring insulin treatment;
9. Hyperthyroidism during pregnancy;
10. Pathologic birth presentation;
11. Abnormal Cardiotocogram for more than 2 hours at day of delivery;
12. Preterm birth before 37th week of gestation;
13. Probiotic and prebiotic supplementation during the last 2 weeks of gestation;
14. Mothers treated for infertility;
15. Placenta implementation;
16. Any known atopic diseases or food allergies in family history;
17. Investigator°Įs uncertainty about the willingness or ability of the subject to comply with the protocol requirements.

For the neonates:
1. Any known congenital disease which could interfere with the study conduct and assessments;
2. Any serious disease that could interfere with the study conduct and assessments;
3. Abnormal birth weight (normal ranges: girls 2.7 ®C 5 kg; boys 2.9 ®C 5.2 kg);
4. Apgar score < 7 after 10 min;
5. Any medical condition requiring antibiotic therapy after birth.
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-dec-2009
- planned closingdate1-dec-2010
- Target number of participants180
- InterventionsDuration of intervention: 16 weeks
1. Intervention group:
The participants will receive additional to regular feeding a supplement containing Pre- and Probiotics.
2. Control group:
The control products will be comparable to supplement 1 (excluding the active compound).

The children born vaginally give a reference group. They are breastfed.
- Primary outcomeExploratory Parameters:
1. Composition and metabolic activity of the gut microbiota, assessed by Fluorescent in situ hybridization (FISH) and real time PCR (RT-PCR);
2. Gastrointestinal tolerance;
3. (Serious) adverse events;
4. Anthropometry: anthropometric data will be measured/recorded according to the visits.
- Secondary outcomeN/A
- Timepoints1. 8 personal visits troughout the study duration;
2. 9 stool sample collections throughout the study duration.
- Trial web siteN/A
- statusstopped
- CONTACT FOR PUBLIC QUERIES Kathrin Friedrichs
- CONTACT for SCIENTIFIC QUERIES Kaouther Ben Amor
- Sponsor/Initiator Danone Research B.V.
- Funding
(Source(s) of Monetary or Material Support)
Danone Research B.V.
- PublicationsN/A
- Brief summaryTo investigate the effect of the test product compared to the control product on the development of the gut microbiota, caesarean delivered infants will be randomly allocated to either the intervention group receiving the test product or to the control group receiving a placebo product. The reference group will be represented by vaginal delivered, breastfed infants. The in- and exclusion criteria are chosen in a way that only healthy mothers and healthy term born neonates are included in the study. All children will be followed up for 4 weeks after end of intervention. Stool samples will be analysed and safety parameters will be assessed via diary and at the hospital visits.
- Main changes (audit trail)
- RECORD15-dec-2009 - 26-jul-2011


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl